Company
Melbourne, VIC
Every investor coverage indicates participated in a round Acrux raised.
Companies Acrux acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Acrux. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Acrux has hired Dr Jolanta Airey as chief medical officer, adding clinical leadership as the company prepares late-stage trials in the United States for its women's testosterone therapy.
Melbourne drug developer Hatchtech raised A$12.6 million, with OneVentures Innovation Fund leading, to advance its head lice treatment toward Phase III trials; board changes brought in Richard Treagus and Hugh Alsop.